Insulet Corporation ($PODD) Stock Forecast: Down 5.2% Today

What is Insulet Corporation?

Insulet Corporation (PODD) is a medical device company specializing in tubeless insulin pump technology, particularly known for its Omnipod Insulin Management System.

Why is Insulet Corporation going down?

PODD stock is down 5.2% on Mar 13, 2026 13:56

• The decline in Insulet's stock (PODD) today is tied to a voluntary correction made by the company concerning specific lots of Omnipod 5 Pods due to a manufacturing problem causing insulin leaks. This has raised concerns about product safety and potential revenue impact.
• Negative information about the insulin leak issue may have overshadowed favorable study results released by Insulet Corporation on a fully closed-loop automated insulin delivery system, which demonstrated promising outcomes for adults with type 2 diabetes. However, the recall news appears to have had a more immediate effect on investor sentiment.
• Furthermore, the decrease in Swiss National Bank holdings may have intensified selling pressure on the stock, suggesting a lack of short-term confidence from institutional investors.
• Despite recent challenges, Insulet's solid Q1 earnings and positive analyst outlook, with a target price of $354.24, suggest favorable long-term growth potential for the company, contingent on resolving the current manufacturing problem and successfully launching their innovative products.

PODD Price Chart

PODD Technical Analysis

PODD News

Is It Time To Reassess Insulet (PODD) After Recent Share Price Weakness

This article analyzes Insulet (PODD) following recent share price weakness, employing Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio analyses to assess its valuation. While the DCF model suggests Insulet is undervalued by 19.2% at US$295.58 per share compared to its current price of US$238.82, its P/E ratio of 68.04x is found to be overvalued compared to its industry average and Simply Wall St's Fair Ratio of 32.64x. The article encourages investors to use Simply Wall St's "Narratives" feature for a more personalized valuation approach.

https://www.sahmcapital.com/news/content/is-it-time-to-reassess-insulet-podd-after-recent-share-price-weakness-2026-03-12

INSULET recalls specific Omnipod 5 pods due to insulin leak risk

Insulet Corporation initiated a voluntary medical device correction for specific lots of Omnipod 5 Pods due to a manufacturing issue that could cause insulin leaks, potentially leading to high blood glucose levels. The company has received 18 reports of serious adverse events, including hospitalization and diabetic ketoacidosis, but no deaths. This correction affects approximately 1.5% of annual Omnipod 5 pod production globally and applies only to specific lots distributed in the United States, with the company having implemented updated manufacturing and quality controls.

https://www.streetinsider.com/Corporate+News/INSULET+recalls+specific+Omnipod+5+pods+due+to+insulin+leak+risk/26152943.html

Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.

Insulet Corporation has initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods in the U.S. due to a manufacturing issue that could cause insulin leakage and lead to high blood glucose levels or DKA. While 18 serious adverse events have been reported, no deaths have occurred, and only about 1.5% of annual Omnipod® 5 production is affected. Insulet has updated its manufacturing processes and customers can check their Pod lot numbers and request free replacements.

https://www.businesswire.com/news/home/20260312976912/en/Insulet-Initiates-Voluntary-Medical-Device-Correction-for-Certain-Omnipod-5-Pods-in-the-U.S.

Swiss National Bank Reduces Position in Insulet Corporation $PODD

The Swiss National Bank reduced its holdings in Insulet Corporation (NASDAQ:PODD) by 4.6% in the third quarter, selling 9,800 shares to own 202,800 shares valued at $62.61 million. Other institutional investors like Vanguard Group Inc., Geode Capital Management LLC, Norges Bank, Federated Hermes Inc., and Charles Schwab Investment Management Inc. either increased their positions or initiated new stakes in the company. Insulet recently reported strong Q1 earnings, surpassing analyst estimates, and analysts have an average "Moderate Buy" rating with a target price of $354.24.

https://www.marketbeat.com/instant-alerts/filing-swiss-national-bank-reduces-position-in-insulet-corporation-podd-2026-03-12/

Insulet Corporation Presents Promising Study Results For Fully Closed-Loop Automated Insulin Delivery System For Adults With Type 2 Diabetes

Insulet Corporation announced promising results from its EVOLUTION 2 study for a fully closed-loop automated insulin delivery system, designed for adults with type 2 diabetes. The study showed a significant increase in time in range to 68% without manual boluses and very low time below range, with no severe hypoglycemia or diabetic ketoacidosis events observed. These findings build on previous research and pave the way for a pivotal study in 2026, aiming for commercial launch in 2028.

https://www.marketscreener.com/news/insulet-corporation-presents-promising-study-results-for-fully-closed-loop-automated-insulin-deliver-ce7e5fdddf8af724

Trending Today

Capri Holdings Limited ($CPRI) Stock Forecast: Up 5.3% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 5.2% Today

Mosaic Company (The) ($MOS) Stock Forecast: Down 6.0% Today

CF Industries Holdings Inc. ($CF) Stock Forecast: Down 5.2% Today

Silver ($XAG) Commodity Forecast: Down 5.3% Today

Lamb Weston Holdings Inc. ($LW) Stock Forecast: Down 5.4% Today

CDW Corporation ($CDW) Stock Forecast: Down 5.0% Today

Southwest Airlines Company ($LUV) Stock Forecast: Down 5.3% Today

Workday Inc. ($WDAY) Stock Forecast: Down 5.0% Today

General Dynamics Corporation ($GD) Stock Forecast: Down 0.6% Today

Insulet Corporation Price History

10.01.2026 - PODD Stock was up 5.1%

• A significant increase in stake by BI Asset Management Fondsmaeglerselskab A S indicates confidence in Insulet Corporation's future prospects, likely contributing to the bullish movement in the stock.
• The launch of Insulet's Omnipod 5 Automated Insulin Delivery System in new markets like the Middle East showcases the company's commitment to expanding its product offerings and reaching a broader customer base, potentially boosting investor optimism.
• Despite the recent stock decline and trading below analyst targets, the introduction of innovative products such as Omnipod Discover and the company's focus on ecosystem enhancement could be positively received by investors, leading to the bullish market movement.

13.02.2026 - PODD Stock was down 5.2%

• The decline in Insulet's stock (PODD) today is tied to a voluntary correction made by the company concerning specific lots of Omnipod 5 Pods due to a manufacturing problem causing insulin leaks. This has raised concerns about product safety and potential revenue impact.
• Negative information about the insulin leak issue may have overshadowed favorable study results released by Insulet Corporation on a fully closed-loop automated insulin delivery system, which demonstrated promising outcomes for adults with type 2 diabetes. However, the recall news appears to have had a more immediate effect on investor sentiment.
• Furthermore, the decrease in Swiss National Bank holdings may have intensified selling pressure on the stock, suggesting a lack of short-term confidence from institutional investors.
• Despite recent challenges, Insulet's solid Q1 earnings and positive analyst outlook, with a target price of $354.24, suggest favorable long-term growth potential for the company, contingent on resolving the current manufacturing problem and successfully launching their innovative products.

20.01.2026 - PODD Stock was down 5.8%

• Insulet Corporation (PODD) witnessed a downturn in its stock, despite strong Q4 results and an expansion of its share repurchase program.
• The stock's decline may be linked to JPMorgan Chase & Co. revising Insulet's price target downward from $415.00 to $340.00 due to cautious guidance, despite robust earnings and revenue growth.
• Other factors contributing to the bearish movement include concerns about the company's valuation, competitive landscape in the diabetes market, and technical challenges like trading below its moving averages.
• The market sentiment appears mixed, with positive financial performance offset by underlying uncertainties, resulting in selling pressure on the stock.

19.01.2026 - PODD Stock was down 5.6%

• Despite a strong Q4 performance showing a 31% revenue growth and surpassing earnings expectations, Insulet's stock (PODD) faced a 5.6% decline.
• The market response was negative due to Insulet's conservative short-term outlook, which overshadowed its solid financial results and expansion initiatives.
• A reduction in price target by a major financial institution from $415.00 to $340.00, though still affirming an "overweight" rating, added to the stock's downward trend.
• Investor apprehension regarding the potential effects of the cautious guidance on Insulet's future growth trajectory likely contributed to the stock's decline, despite the positive earnings outcome.

19.01.2026 - PODD Stock was down 6.8%

• A significant number of shares of Insulet Corporation were acquired by Cumberland Partners Ltd, indicating confidence in the company's future prospects.
• Insulet's stock price target was lowered by Canaccord Genuity due to valuation concerns, despite the company reporting strong Q4 earnings and revenue growth.
• Impressive financial results for Q4 and full year 2025 were reported by Insulet, showing consistent revenue growth and strategic developments in the diabetes management market.
• The market may have reacted bearishly to the lowered price target by Canaccord Genuity, overshadowing the positive earnings and growth reported by Insulet.

19.01.2026 - PODD Stock was down 6.0%

• In recent quarters, Insulet Corporation recorded strong Q4 earnings and revenue surpassing expectations. Despite the impressive growth in Omnipod revenues and a positive outlook, the company's stock saw a decline.
• One factor contributing to the stock's downturn is a decrease in Insulet's stock price target by Canaccord Genuity. This adjustment reflects industry valuation compression, despite the strong financial performance of the company.
• The purchase of shares by Cumberland Partners Ltd and other institutional investors initially instilled confidence in the stock but was insufficient to counter the prevailing market sentiment.
• Following Insulet's mention of challenging year-over-year comparisons, investors engaged in profit-taking, resulting in a bearish trend in the stock price.

18.01.2026 - PODD Stock was up 5.3%

• Insulet (PODD) shares rose by 5.6% post the disclosure of robust fourth-quarter financial results that surpassed expectations, attributed to heightened demand for its Omnipod insulin management systems.
• The company's positive projection of a 26% year-over-year sales upsurge for the first quarter of 2026 added to the stock's upward momentum.
• Despite a previous decline of 7.9% since the year's commencement, the recent favorable performance suggests that investors may have found confidence in the company's financial strength and strategic initiatives.
• Insulet's focus on innovation, market expansion, and precise execution in transforming diabetes care likely fostered investor trust, fueling the notable increase in the stock price.

23.00.2026 - PODD Stock was down 5.1%

• Insulet Corporation (PODD) had a bearish movement possibly due to the following reasons:
• Despite surpassing EPS estimates, the company missed revenue expectations, which might have disappointed investors.
• The significant reduction in stake by SG Americas Securities LLC could have signaled a lack of confidence in the company's future performance.
• The appointment of a new CEO at BVI, who was the former CEO of Insulet, might have raised concerns about leadership stability at Insulet.
• Although Stephens Investment Management Group LLC increased its stake, the overall market sentiment could have been influenced by the mixed signals from institutional investors.

18.01.2026 - PODD Stock was up 9.2%

• Following the Q4 2025 earnings announcement, Insulet Corporation (PODD) saw a notable uptrend today.
• While falling slightly short of EPS projections, the company surpassed revenue estimations and achieved a remarkable 31.2% year-over-year revenue expansion.
• An increase of $350 million in share repurchase authorization and optimistic 2026 guidance were divulged, underlining Insulet's financial robustness and confidence in future growth.
• Market reception to Insulet's effective operations, solid business model, and success in diabetes care has bolstered investor trust, propelling the stock price upward in a bullish fashion.

06.10.2025 - PODD Stock was down 5.7%

• Increased short interest in Insulet Corp (PODD) potentially contributed to the bearish movement.
• Wall Street estimates for key metrics ahead of Insulet's Q3 earnings may have fallen short, affecting investor sentiment.
• The overall market performance and potential profit-taking activities likely influenced the bearish movement in Insulet's stock.
• Investors might be reacting to current market conditions and short-term factors impacting Insulet's stock price negatively, despite its historical outperformance.

20.10.2025 - PODD Stock was down 2.0%

• Today's decline in Insulet's stock could be linked to profit-taking following a sustained period of impressive performance.
• An uptick in activity from options traders may have contributed to increased volatility and selling activity in the stock.
• Despite the recent setback, positive earnings estimate revisions indicate that Insulet is positioned favorably for a potential upswing in the near term.

20.10.2025 - PODD Stock was down 6.2%

• The growing short interest could be influencing the stock's decline as more investors are taking positions against the company.
• Despite Insulet's strong performance in the past 15 years, it seems insufficient to counter the prevailing negative market sentiment, resulting in a drop in the stock price.
• Activities in the options market indicate potential insider information or speculative trading affecting the stock, intensifying the bearish outlook.